FDA Limits Use of Johnson & Johnson COVID-19 Vaccine Due to Risk of Rare Blood Clots
May 6th 2022FDA action was based on an analysis for the risk of thrombosis with thrombocytopenia syndrome, a rare and potentially life-threatening condition that causes blood clots combined with low levels of blood platelets.
Read More
FDA Approves Trastuzumab Deruxtecan for Certain Patients With HER2-Positive Metastatic Breast Cancer
May 5th 2022Trastuzumab deruxtecan (Enhertu) approved for adult patients with unresectable or metastatic HER2-positive breast cancer who were previously administered an anti–HER2-based regimen.
Read More